ClinicalTrials.gg
TerminatedNCT00281528Updated Nov 22, 2019Results posted

Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer

A Phase 2 interventional study of ABI-007 (Abraxane) and bevacizumab in Breast Neoplasms and Neoplasm Metastasis, sponsored by Celgene. Terminated at 40 sites in 2 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-22.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

Why this study was terminated
sufficient mature data to complete a final analysis

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
208
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 108 studies testing Albumin-Bound Paclitaxel in Breast Neoplasms — 18 open to participants now, 22 under way, 2 of them phase 3. Albumin-Bound Paclitaxel · Breast Neoplasms.

Enrollment
18th of 108
208 · median 60
Started
2006
with 8 others
Phase 2
67 of 108
9 open now
Registered
10th of 108
by date
Lead sponsor
9 of 108
Celgene

Among the 108 studies testing Albumin-Bound Paclitaxel in Breast Neoplasms, this one is the 18th largest by enrollment, is one of 9 that started in 2006, is one of 67 in phase 2, and was the 10th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

18 of the 108 studies testing Albumin-Bound Paclitaxel in Breast Neoplasms are open now, in 10 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About Albumin-Bound Paclitaxel

Albumin-Bound Paclitaxel: first FDA approval 2005 (ABRAXANE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 108 studies testing Albumin-Bound Paclitaxel in Breast Neoplasms, or all of them as a file.
02

Study summary

This is a multi-center, open-label, randomized Phase II study in previously untreated patients with metastatic breast cancer to evaluate the antitumor activity and safety of weekly dose-dense ABI-007 (Abraxane) compared to 2-weekly regimen vs the standard 3-weekly infusion. All patients will also receive concurrent bevacizumab.

03

Conditions studied

  • Breast Neoplasms
  • Neoplasm Metastasis

Keywords

  • First Line Metastatic Breast Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed adenocarcinoma of the breast.
  • Stage IV disease
  • Patients must not be a candidate for Herceptin therapy
  • At least 4 weeks since radiotherapy, with full recovery. The measurable disease must be completely outside the radiation portal or there must be pathologic proof of progressive disease within the radiation portal.
  • At least 4 weeks since major surgery, with full recovery.
  • (ECOG) performance status 0-2.
  • Female >18 years of age.
  • Patient has the following blood counts at Baseline:

≥ 1.5 x 10\^9cells/L; ≥ 100 x 10\^9 cells/L; ≥ 9 g/dL.

  • Patient has the following blood chemistry levels at Baseline: (AST or SGOT), alanine aminotransferase (ALT or SGPT) ≤ 2.5x (ULN); total ≤ ULN; creatinine ≤ 1.5 mg/dL.
  • If female of , pregnancy test is negative within 72 hours of first dose of study drug.
  • If fertile, the patient agrees to use an effective method to avoid pregnancy for the duration of the study.
  • has been obtained.

Exclusion criteria

Exclusion Criteria:

  • Prior or adjuvant chemotherapy is allowed, and patients must have recovered from the acute toxicity of such therapies. No prior therapy for disease is allowed. If a taxane was part of the adjuvant regimen, at least 12 months should have passed from completion of taxane regimen to relapse. If a non-taxane-based adjuvant therapy was administered, at least 6 months should have passed from completion to relapse.
  • Concurrent immunotherapy or hormonal therapy.
  • Parenchymal , including .
  • Inadequately controlled hypertension (defined as blood pressure of > 150/100 mmHg) or (NYHA) Grade 2 or greater congestive heart failure.
  • Any prior history of hypertensive crisis or hypertensive encephalopathy.
  • History of myocardial infarction or unstable angina within 6 months prior to study enrollment.
  • History of stroke or within 6 months prior to study enrollment.
  • Significant vascular disease (e.g., aortic aneurysm, aortic dissection).
  • Symptomatic peripheral vascular disease.
  • Evidence of bleeding diathesis or coagulopathy.
  • History of abdominal fistula, gastrointestinal perforation, or intra- abdominal abscess within 6 months prior to study enrollment.
  • Proteinuria at screening as demonstrated by either: - Urine protein:creatinine (UPC) ratio > 1.0 at screening OR - Urine dipstick for proteinuria ≥ 2+ (patients discovered to have ≥ 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection and must demonstrate ≤ 1g of protein in 24 hours to be eligible).
  • Known to any component of bevacizumab.
  • Core or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to first dose.
  • Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to first dose, anticipation of need for major surgical procedure during the course of the study. Serious, non-healing wound, ulcer, or bone fracture. Serious intercurrent medical or psychiatric illness, including serious active infection.
  • History of other within the last 5 years which could affect the diagnosis or assessment of breast cancer.
  • Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study.
  • Pregnant or nursing women.
  • Sensory neuropathy of > Grade 1 at baseline.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
208 participants (actual)

Study arms

  • Experimental
    260 mg/m^2 ABI-007 every 3 weeks

    260 mg/m\^2 every 3 weeks and 15 mg/kg bevacizumab every 3 weeks

    Drug: ABI-007 (Abraxane) · Drug: bevacizumab

  • Experimental
    260 mg/m^2 ABI-007 every 2 weeks

    260 mg/m\^2 ABI-007 every 2 weeks and 10 mg/kg bevacizumab every 2 weeks

    Drug: ABI-007 (Abraxane) · Drug: bevacizumab

  • Experimental
    130 mg/m^2 ABI-007 weekly

    130 mg/m\^2 ABI-007 weekly (without a week of 'rest') and 10 mg/kg bevacizumab every 2 weeks

    Drug: ABI-007 (Abraxane) · Drug: bevacizumab

Interventions

06

What researchers measure

Primary outcomes

  1. The Percentage of Participants Confirmed Complete Response (CR) or Partial Response (PR) Based on Response Evaluation Criteria In Solid Tumors (RECIST v1.0)

    Using the RECIST response criteria version 1.0, the percent of participants achieving either a complete response (CR) defined as the disappearance of all known disease and no new sites or disease related symptoms confirmed at least 4 weeks after initial documentation or partial response (PR) defined as at least a 30% decrease in the sum of the longest diameters of target lesions and no progression in non-target lesions based on confirmed responses from the investigator assessment of best overall response during study treatment.

    Time frame: Up to 43 months

  2. Participant Counts of the Most Severe Grade for Absolute Neutrophil (ANC) as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3)

    Myelosuppression is a decrease in the ability of the bone marrow to produce blood cells. The lowest measured (nadir) ANC counts were graded using NCI CTCAE version 3: Grade 0 = within normal limits; Grade 1 = \< lower limit of normal - 75.0\*10\^9L; Grade 2 = \<1.5 - 1.0\*10\^9L; Grade 3 = \<1.0 - 0.5\*10\^9L; Grade 4 = \<0.5\*10\^9L

    Time frame: up to 54 months

  3. Participant Counts of the Most Severe Grade for White Blood Cells (WBC) as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3)

    Myelosuppression is a decrease in the ability of the bone marrow to produce blood cells. The lowest measured (nadir) WBC counts were graded using NCI CTCAE version 3: Grade 0 = within normal limits; Grade 1 = \< lower limit of normal -3.0\*10\^9/L; Grade 2 = \<3.0 - 2.0\*10\^9/L; Grade 3 = \<2.0 - 1.0\*10\^9/L; Grade 4 = \<1.0\*10\^9/L

    Time frame: up to 54 months

  4. Participant Counts of the Most Severe Grade for Platelet Counts as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3)

    Myelosuppression is a decrease in the ability of the bone marrow to produce blood cells. The lowest measured (nadir) platelet counts were graded using NCI CTCAE version 3: Grade 0 = within normal limits; Grade 1 = \< lower limit of normal - 75.0\*10\^9/L; Grade 2 = \<75.0 - 50.0\*10\^9/L; Grade 3 = \<50.0 - 25.0\*10\^9/L; Grade 4 = \<25.0\*10\^9/L

    Time frame: up to 54 months

  5. Participant Counts of the Most Severe Grade for Hemoglobin Levels as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3)

    Myelosuppression is a decrease in the ability of the bone marrow to produce blood cells. The lowest measured (nadir) hemoglobin levels were graded using NCI CTCAE version 3: Grade 0 = within normal limits; Grade 1 = \< lower limit of normal - 100g/L; Grade 2 = \<100 - 80g/L; Grade 3 = \<80 - 65g/L; Grade 4 = \<65g/L

    Time frame: up to 54 months

  6. The Number of Participants With at Least One Dose Reduction for ABI-007

    Participants with at least one dose reduction for ABI-007. ABI-007 (Abraxane) dose could be reduced according to protocol guidelines if the participant was experiencing toxicities. Participants were allowed two ABI-007 (Abraxane) dose reductions during the course of the trial. This outcome is considered to be both a safety and an efficacy outcome.

    Time frame: Up to 53 months

  7. The Number of Participants With at Least One Dose Delay for ABI-007

    Participants with at least one dose delay for ABI-007. Treatment delays of no longer than 2 weeks allowed participants to recovery from acute toxicity. If treatment was delayed beyond 2 weeks, continuing treatment on protocol was at the physician's discretion, based upon the best interests of the participant. This outcome is considered to be both a safety and an efficacy outcome.

    Time frame: Up to 53 months

  8. The Number of Participants With a Dose Interruption of ABI-007

    Number of participants who interrupted (omitted) a dose at some point in the treatment period. This outcome is considered to be both a safety and an efficacy outcome.

    Time frame: Up to 53 months

Secondary outcomes

  1. Percentage of Participants With Stable Disease for ≥ 16 Weeks, or Complete or Partial Overall Response (i.e., Total Response) Based on Response Evaluation Criteria In Solid Tumors (RECIST v1.0)

    Using Response Evaluation Criteria in Solid Tumors (RECIST v1.0), the percentage of participants achieving either * A complete response (CR) defined as the disappearance of all known disease and no new sites or disease related symptoms confirmed at least 4 weeks after initial documentation or * A partial response (PR) defined as at least a 30% decrease in the sum of the longest diameters of target lesions and no progression in non-target lesions or * Stable disease (SD) defined as neither sufficient shrinkage to qualify for PR or sufficient increase to qualify for progressive disease.

    Time frame: Up to 43 months (until progressed)

  2. Kaplan Meier Estimate for Time to Disease Progression (TTP)

    Time to progression was defined as the time from the first dose of study drug to the start of progression. Participants that did not have progression were censored at the last known time the patient was evaluated for progression. Participants that initiate other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated. Progressive disease was defined as at least a 20% increase in the sum of the longest diameters of target lesions; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion.

    Time frame: Up to 43 months (until progressed)

  3. Kaplan Meier Estimate for Duration of Response

    Duration of response was defined as the time from response to the time of disease progression for participants who achieve an objective confirmed complete (CR) or partial overall response (PR). Disease progression is based on the assessments by the investigator. Participants who did not have disease progression following a confirmed complete or partial target response were censored at the last known time that the participant was evaluated for response

    Time frame: Up to 43 months (until progressed)

  4. Kaplan Meier Estimate for Participant Survival

    Participant survival was summarized using Kaplan-Meier estimate of the time of first dose of study drug to the last known time that the participant was alive. Participants that were alive at the end of follow-up would be censored at the last known time that the patient was alive.

    Time frame: Up to 56 months

  5. Kaplan Meier Estimate for Progression-Free Survival (PFS)

    PFS was defined as the time from the first dose of study drug to the start of progression or patient death (any cause) whichever occurred first. Participants that did not have progression or have not died were censored at the last known time the participant was progression free. Participants that initiate other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated.

    Time frame: up to 56 months

07

Results

Posted Mar 13, 2012

Participant flow

Participant flow — Overall Study
Milestone260 mg/m^2 ABI-007 Every 3 Weeks260 mg/m^2 ABI-007 Every 2 Weeks130 mg/m^2 ABI-007 Weekly
Started755479
Completed000
Not completed755479
Withdrew: Progressive disease281827
Withdrew: Unacceptable toxicity-related to trt212432
Withdrew: Adverse event-unrelated to treatment302
Withdrew: Physician decision1145
Withdrew: Protocol violation101
Withdrew: Withdrawal by subject557
Withdrew: Other635

Outcome measures

PrimaryThe Percentage of Participants Confirmed Complete Response (CR) or Partial Response (PR) Based on Response Evaluation Criteria In Solid Tumors (RECIST v1.0)

Using the RECIST response criteria version 1.0, the percent of participants achieving either a complete response (CR) defined as the disappearance of all known disease and no new sites or disease related symptoms confirmed at least 4 weeks after initial documentation or partial response (PR) defined as at least a 30% decrease in the sum of the longest diameters of target lesions and no progression in non-target lesions based on confirmed responses from the investigator assessment of best overall response during study treatment.

Time frame:
Up to 43 months
Reported as:
Number · Percent of Total Participants
The Percentage of Participants Confirmed Complete Response (CR) or Partial Response (PR) Based on Response Evaluation Criteria In Solid Tumors (RECIST v1.0)
Percent of Total Participants260 mg/m^2 ABI-007 Every 3 Weeks260 mg/m^2 ABI-007 Every 2 Weeks130 mg/m^2 ABI-007 Weekly
The Percentage of Participants Confirmed Complete Response (CR) or Partial Response (PR) Based on Response Evaluation Criteria In Solid Tumors (RECIST v1.0)414347
Statistical analysis
  • 260 mg/m^2 ABI-007 Every 3 Weeks vs 130 mg/m^2 ABI-007 Weekly · Cochran-Mantel-Haenszel · p = 0.4476 (Group comparison was performed between group 260 mg/m\^2 ABI-007 every 3 weeks and group 130 mg/m\^2 ABI-007 weekly, as based on amended protocol, no type I error adjustment for multiplicity; a priori threshold for statistical significance is 0.05.)Stratified by study site
SecondaryPercentage of Participants With Stable Disease for ≥ 16 Weeks, or Complete or Partial Overall Response (i.e., Total Response) Based on Response Evaluation Criteria In Solid Tumors (RECIST v1.0)

Using Response Evaluation Criteria in Solid Tumors (RECIST v1.0), the percentage of participants achieving either * A complete response (CR) defined as the disappearance of all known disease and no new sites or disease related symptoms confirmed at least 4 weeks after initial documentation or * A partial response (PR) defined as at least a 30% decrease in the sum of the longest diameters of target lesions and no progression in non-target lesions or * Stable disease (SD) defined as neither sufficient shrinkage to qualify for PR or sufficient increase to qualify for progressive disease.

Time frame:
Up to 43 months (until progressed)
Reported as:
Number · Percent of Total Participants
Percentage of Participants With Stable Disease for ≥ 16 Weeks, or Complete or Partial Overall Response (i.e., Total Response) Based on Response Evaluation Criteria In Solid Tumors (RECIST v1.0)
Percent of Total Participants260 mg/m^2 ABI-007 Every 3 Weeks260 mg/m^2 ABI-007 Every 2 Weeks130 mg/m^2 ABI-007 Weekly
Percentage of Participants With Stable Disease for ≥ 16 Weeks, or Complete or Partial Overall Response (i.e., Total Response) Based on Response Evaluation Criteria In Solid Tumors (RECIST v1.0)655258
PrimaryParticipant Counts of the Most Severe Grade for Absolute Neutrophil (ANC) as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3)

Myelosuppression is a decrease in the ability of the bone marrow to produce blood cells. The lowest measured (nadir) ANC counts were graded using NCI CTCAE version 3: Grade 0 = within normal limits; Grade 1 = \< lower limit of normal - 75.0\*10\^9L; Grade 2 = \<1.5 - 1.0\*10\^9L; Grade 3 = \<1.0 - 0.5\*10\^9L; Grade 4 = \<0.5\*10\^9L

Time frame:
up to 54 months
Reported as:
Number · participants
Participant Counts of the Most Severe Grade for Absolute Neutrophil (ANC) as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3)
participants260 mg/m^2 ABI-007 Every 3 Weeks260 mg/m^2 ABI-007 Every 2 Weeks130 mg/m^2 ABI-007 Weekly
Grade 051 ± 1.56934 ± 3.21617 ± .750
Grade 15517
Grade 22617
Grade 33417
Grade 4202
SecondaryKaplan Meier Estimate for Time to Disease Progression (TTP)

Time to progression was defined as the time from the first dose of study drug to the start of progression. Participants that did not have progression were censored at the last known time the patient was evaluated for progression. Participants that initiate other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated. Progressive disease was defined as at least a 20% increase in the sum of the longest diameters of target lesions; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion.

Time frame:
Up to 43 months (until progressed)
Reported as:
Median · Months
Kaplan Meier Estimate for Time to Disease Progression (TTP)
Months260 mg/m^2 ABI-007 Every 3 Weeks260 mg/m^2 ABI-007 Every 2 Weeks130 mg/m^2 ABI-007 Weekly
Kaplan Meier Estimate for Time to Disease Progression (TTP)8.0 (7.0 to 10.3)6.3 (5.3 to 8.0)9.0 (7.2 to 11.1)
SecondaryKaplan Meier Estimate for Duration of Response

Duration of response was defined as the time from response to the time of disease progression for participants who achieve an objective confirmed complete (CR) or partial overall response (PR). Disease progression is based on the assessments by the investigator. Participants who did not have disease progression following a confirmed complete or partial target response were censored at the last known time that the participant was evaluated for response

Time frame:
Up to 43 months (until progressed)
Reported as:
Median · Months
Kaplan Meier Estimate for Duration of Response
Months260 mg/m^2 ABI-007 Every 3 Weeks260 mg/m^2 ABI-007 Every 2 Weeks130 mg/m^2 ABI-007 Weekly
Kaplan Meier Estimate for Duration of Response10.3 (8.0 to 12.3)8.0 (5.5 to 13.4)9.9 (7.7 to 15.7)
SecondaryKaplan Meier Estimate for Participant Survival

Participant survival was summarized using Kaplan-Meier estimate of the time of first dose of study drug to the last known time that the participant was alive. Participants that were alive at the end of follow-up would be censored at the last known time that the patient was alive.

Time frame:
Up to 56 months
Reported as:
Median · Months
Kaplan Meier Estimate for Participant Survival
Months260 mg/m^2 ABI-007 Every 3 Weeks260 mg/m^2 ABI-007 Every 2 Weeks130 mg/m^2 ABI-007 Weekly
Kaplan Meier Estimate for Participant Survival21.3 (19.5 to 26.6)19.0 (15.0 to 28.1)23.7 (18.2 to 31.0)
PrimaryParticipant Counts of the Most Severe Grade for White Blood Cells (WBC) as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3)

Myelosuppression is a decrease in the ability of the bone marrow to produce blood cells. The lowest measured (nadir) WBC counts were graded using NCI CTCAE version 3: Grade 0 = within normal limits; Grade 1 = \< lower limit of normal -3.0\*10\^9/L; Grade 2 = \<3.0 - 2.0\*10\^9/L; Grade 3 = \<2.0 - 1.0\*10\^9/L; Grade 4 = \<1.0\*10\^9/L

Time frame:
up to 54 months
Reported as:
Number · participants
Participant Counts of the Most Severe Grade for White Blood Cells (WBC) as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3)
participants260 mg/m^2 ABI-007 Every 3 Weeks260 mg/m^2 ABI-007 Every 2 Weeks130 mg/m^2 ABI-007 Weekly
Grade 0473011
Grade 191421
Grade 26526
Grade 32011
Grade 4001
PrimaryParticipant Counts of the Most Severe Grade for Platelet Counts as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3)

Myelosuppression is a decrease in the ability of the bone marrow to produce blood cells. The lowest measured (nadir) platelet counts were graded using NCI CTCAE version 3: Grade 0 = within normal limits; Grade 1 = \< lower limit of normal - 75.0\*10\^9/L; Grade 2 = \<75.0 - 50.0\*10\^9/L; Grade 3 = \<50.0 - 25.0\*10\^9/L; Grade 4 = \<25.0\*10\^9/L

Time frame:
up to 54 months
Reported as:
Number · participants
Participant Counts of the Most Severe Grade for Platelet Counts as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3)
participants260 mg/m^2 ABI-007 Every 3 Weeks260 mg/m^2 ABI-007 Every 2 Weeks130 mg/m^2 ABI-007 Weekly
Grade 0603964
Grade 12104
Grade 2101
Grade 3000
Grade 4000
PrimaryParticipant Counts of the Most Severe Grade for Hemoglobin Levels as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3)

Myelosuppression is a decrease in the ability of the bone marrow to produce blood cells. The lowest measured (nadir) hemoglobin levels were graded using NCI CTCAE version 3: Grade 0 = within normal limits; Grade 1 = \< lower limit of normal - 100g/L; Grade 2 = \<100 - 80g/L; Grade 3 = \<80 - 65g/L; Grade 4 = \<65g/L

Time frame:
up to 54 months
Reported as:
Number · participants
Participant Counts of the Most Severe Grade for Hemoglobin Levels as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3)
participants260 mg/m^2 ABI-007 Every 3 Weeks260 mg/m^2 ABI-007 Every 2 Weeks130 mg/m^2 ABI-007 Weekly
Grade 0412513
Grade 1171833
Grade 26619
Grade 3004
Grade 4001
PrimaryThe Number of Participants With at Least One Dose Reduction for ABI-007

Participants with at least one dose reduction for ABI-007. ABI-007 (Abraxane) dose could be reduced according to protocol guidelines if the participant was experiencing toxicities. Participants were allowed two ABI-007 (Abraxane) dose reductions during the course of the trial. This outcome is considered to be both a safety and an efficacy outcome.

Time frame:
Up to 53 months
Reported as:
Number · Participants
The Number of Participants With at Least One Dose Reduction for ABI-007
Participants260 mg/m^2 ABI-007 Every 3 Weeks260 mg/m^2 ABI-007 Every 2 Weeks130 mg/m^2 ABI-007 Weekly
The Number of Participants With at Least One Dose Reduction for ABI-007363253
PrimaryThe Number of Participants With at Least One Dose Delay for ABI-007

Participants with at least one dose delay for ABI-007. Treatment delays of no longer than 2 weeks allowed participants to recovery from acute toxicity. If treatment was delayed beyond 2 weeks, continuing treatment on protocol was at the physician's discretion, based upon the best interests of the participant. This outcome is considered to be both a safety and an efficacy outcome.

Time frame:
Up to 53 months
Reported as:
Number · Participants
The Number of Participants With at Least One Dose Delay for ABI-007
Participants260 mg/m^2 ABI-007 Every 3 Weeks260 mg/m^2 ABI-007 Every 2 Weeks130 mg/m^2 ABI-007 Weekly
The Number of Participants With at Least One Dose Delay for ABI-007402768
PrimaryThe Number of Participants With a Dose Interruption of ABI-007

Number of participants who interrupted (omitted) a dose at some point in the treatment period. This outcome is considered to be both a safety and an efficacy outcome.

Time frame:
Up to 53 months
Reported as:
Number · Participants
The Number of Participants With a Dose Interruption of ABI-007
Participants260 mg/m^2 ABI-007 Every 3 Weeks260 mg/m^2 ABI-007 Every 2 Weeks130 mg/m^2 ABI-007 Weekly
The Number of Participants With a Dose Interruption of ABI-007200
SecondaryKaplan Meier Estimate for Progression-Free Survival (PFS)

PFS was defined as the time from the first dose of study drug to the start of progression or patient death (any cause) whichever occurred first. Participants that did not have progression or have not died were censored at the last known time the participant was progression free. Participants that initiate other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated.

Time frame:
up to 56 months
Reported as:
Median · months
Kaplan Meier Estimate for Progression-Free Survival (PFS)
months260 mg/m^2 ABI-007 Every 3 Weeks260 mg/m^2 ABI-007 Every 2 Weeks130 mg/m^2 ABI-007 Weekly
Kaplan Meier Estimate for Progression-Free Survival (PFS)7.7 (7.3 to 8.8)6.3 (5.3 to 8.0)8.8 (5.8 to 9.9)

Adverse events

Collected over Up to 54 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
260 mg/m^2 ABI-007 Every 3 Weeks—22/75 (29.3%)75/75 (100%)
260 mg/m^2 ABI-007 Every 2 Weeks—16/54 (29.6%)54/54 (100%)
130 mg/m^2 ABI-007 Weekly—32/79 (40.5%)78/79 (98.7%)
Most frequent serious events
Showing 10 of 71
Most frequent serious events
Event260 mg/m^2 ABI-007 Every 3 Weeks260 mg/m^2 ABI-007 Every 2 Weeks130 mg/m^2 ABI-007 Weekly
DehydrationMetabolism and nutrition disorders2/752/545/79
VomitingGastrointestinal disorders1/751/544/79
DiarrhoeaGastrointestinal disorders0/750/543/79
NeuropathyNervous system disorders0/752/542/79
Cardiac failure congestiveCardiac disorders2/750/540/79
Pulmonary embolismRespiratory, thoracic and mediastinal disorders2/751/542/79
AnaemiaBlood and lymphatic system disorders0/750/542/79
Mucosal inflammationGeneral disorders0/750/542/79
PyrexiaGeneral disorders0/750/542/79
DiverticulitisInfections and infestations0/750/542/79
Most frequent other events
Showing 10 of 99
Most frequent other events
Event260 mg/m^2 ABI-007 Every 3 Weeks260 mg/m^2 ABI-007 Every 2 Weeks130 mg/m^2 ABI-007 Weekly
FatigueGeneral disorders55/7543/5464/79
AlopeciaSkin and subcutaneous tissue disorders49/7535/5453/79
NauseaGastrointestinal disorders37/7536/5440/79
DiarrhoeaGastrointestinal disorders24/7524/5443/79
EpistaxisRespiratory, thoracic and mediastinal disorders32/7523/5442/79
ConstipationGastrointestinal disorders30/7528/5438/79
Peripheral sensory neuropathyNervous system disorders34/7524/5436/79
NeuropathyNervous system disorders34/7524/5434/79
NeutropeniaBlood and lymphatic system disorders18/759/5431/79
RashSkin and subcutaneous tissue disorders20/7517/5431/79

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)260 mg/m^2 ABI-007 Every 3 Weeks260 mg/m^2 ABI-007 Every 2 Weeks130 mg/m^2 ABI-007 WeeklyTotal
<=18 years0000
Between 18 and 65 years534163157
>=65 years22131651
Age, Customized
Age, Customized(Years)260 mg/m^2 ABI-007 Every 3 Weeks260 mg/m^2 ABI-007 Every 2 Weeks130 mg/m^2 ABI-007 WeeklyTotal
Median59.0 (29.0 to 80.0)56.0 (36.0 to 79.0)56.0 (32.0 to 85.0)57.0 (29.0 to 85.0)
Sex: Female, Male
Sex: Female, Male(Participants)260 mg/m^2 ABI-007 Every 3 Weeks260 mg/m^2 ABI-007 Every 2 Weeks130 mg/m^2 ABI-007 WeeklyTotal
Female755479208
Male0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)260 mg/m^2 ABI-007 Every 3 Weeks260 mg/m^2 ABI-007 Every 2 Weeks130 mg/m^2 ABI-007 WeeklyTotal
Asian1012
Black, of African Heritage11131943
White, Non-Hispanic and Non-Latino523145128
White, Hispanic or Latino8101432
Other (not specified)3003
Weight
Weight(kilograms)260 mg/m^2 ABI-007 Every 3 Weeks260 mg/m^2 ABI-007 Every 2 Weeks130 mg/m^2 ABI-007 WeeklyTotal
Median72.9 (41.8 to 119.5)70.2 (41.4 to 145.0)73.1 (46.0 to 167.8)72.2 (41.4 to 167.8)
Menopausal status
Menopausal status(Participants)260 mg/m^2 ABI-007 Every 3 Weeks260 mg/m^2 ABI-007 Every 2 Weeks130 mg/m^2 ABI-007 WeeklyTotal
Pre-menopausal11111638
Post-menopausal644363170
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)260 mg/m^2 ABI-007 Every 3 Weeks260 mg/m^2 ABI-007 Every 2 Weeks130 mg/m^2 ABI-007 WeeklyTotal
0433348124
129172773
234411
30000
40000
Time from Primary Diagnosis to Study Entry
Time from Primary Diagnosis to Study Entry(Years)260 mg/m^2 ABI-007 Every 3 Weeks260 mg/m^2 ABI-007 Every 2 Weeks130 mg/m^2 ABI-007 WeeklyTotal
Median4.320 (0.025 to 16.901)3.127 (0.041 to 23.932)2.579 (0.022 to 21.065)2.983 (0.022 to 23.932)

1 further baseline measures are reported on the registry.

08

Study locations

40 sites
  • Division of Hematology/Oncology University of Alabama at Birmingham
    Birmingham, Alabama, United States
  • Little Rock Hematology Oncology Associates
    Little Rock, Arkansas, United States
  • California Oncology of the Central Valley
    Fresno, California, United States
  • Glendale Memorial Hospital & Health Center
    Glendale, California, United States
  • Front Range Cancer Specialists
    Fort Collins, Colorado, United States
  • Oncology Associates of Bridgeport
    Bridgeport, Connecticut 06610, United States
  • Palm Beach Institute of Hematology and Oncology
    Boynton Beach, Florida, United States
  • Memorial Cancer Institute/Breast Cancer Center
    Hollywood, Florida 33021, United States
  • Florida Cancer Institute
    Hudson, Florida, United States
  • Hematology Oncology Associates
    Lake Worth, Florida, United States
  • Medical Specialist of the Palm Beaches, Inc
    Lake Worth, Florida, United States
  • Gulfcoast Oncology Associates
    Saint Petersburg, Florida, United States
  • Peachtree Hematology & Oncology Associates
    Atlanta, Georgia, United States
  • Northwest Georgia Oncology Centers, PC
    Marietta, Georgia, United States
  • Center of Hope for Cancers and Blood
    Stockbridge, Georgia 30281, United States
  • Maine Center for Cancer Medicine & Blood Disorders
    Scarborough, Maine, United States
  • Greater Baltimore Medical Center
    Baltimore, Maryland, United States
  • Harbor View Cancer Center
    Baltimore, Maryland, United States
  • Boston Medical Center Moakley Building, Solomont Center for Hematology & Medical Oncology
    Boston, Massachusetts, United States
  • North Shore Medical Cancer Center
    Peabody, Massachusetts 01960, United States
  • St. John's Mercy Medical Center
    Saint Louis, Missouri, United States
  • Nebraska Methodist Hospital
    Omaha, Nebraska, United States
  • Drs. Forte, Schleidere, & Attas, PA
    Englewood, New Jersey, United States
  • Saint Barnabas Medical Center
    Livingston, New Jersey, United States
  • Monmouth Medical Center
    Long Branch, New Jersey, United States
  • Rosewell Park Cancer Institute Elm & Carlton Carlton Building
    Buffalo, New York, United States
  • Beth Israel Comprehensive Cancer Center
    New York, New York, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York, United States
  • NYU Clinical Cancer Center
    New York, New York, United States
  • Marion L. Shepard Cancer Center
    Washington, North Carolina, United States
  • Medical Oncology Aultman Hospital
    Canton, Ohio, United States
  • Cancer Centers of Southwest Oklahoma Research
    Lawton, Oklahoma, United States
  • Abington Hematology Oncology
    Willow Grove, Pennsylvania, United States
  • Family Cancer Center
    Collierville, Tennessee, United States
  • Tennessee Cancer Specialists
    Knoxville, Tennessee, United States
  • TX Oncology, PA
    Austin, Texas, United States
  • South Texas Oncology & Hematology Clinical Research Dept.
    San Antonio, Texas, United States
  • Virginia Commonwealth University Medical Oncology
    Richmond, Virginia, United States
  • Swedish Cancer Institute
    Seattle, Washington, United States
  • Metropolitan Oncology Center
    San Juan, Puerto Rico
09

References and documents

Publications

  • Seidman AD, Conlin AK, Bach A, Moynahan ME, Lake D, Forero A, Wright GS, Hackney MH, Clawson A, Norton L, Hudis CA. Randomized phase II trial of weekly vs. every 2 weeks vs. every 3 weeks nanoparticle albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic breast cancer. Clin Breast Cancer. 2013 Aug;13(4):239-246.e1. doi: 10.1016/j.clbc.2013.02.008. PubMed 23829890 ↗
  • Conlin AK, Seidman AD, Bach A, Lake D, Dickler M, D'Andrea G, Traina T, Danso M, Brufsky AM, Saleh M, Clawson A, Hudis CA. Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer. Clin Breast Cancer. 2010 Aug 1;10(4):281-7. doi: 10.3816/CBC.2010.n.036. PubMed 20705560 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2006 to primary completion in Jul 2010, 53 months.

Results were first posted in Mar 2012, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2006
First posted
Jan 25, 2006
StartActual
Feb 1, 2006
Primary completionActual
Jul 1, 2010
CompletionActual
Mar 1, 2011
Results first posted
Mar 13, 2012
Last update
Nov 22, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 22, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00281528
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Jan 25, 2006
Start date
Feb 1, 2006
Primary completion
Jul 1, 2010
Completion
Mar 1, 2011
Results posted
Mar 13, 2012
Last update
Nov 22, 2019

Study contacts

Andrew Seidman, MD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Albumin-Bound Paclitaxel · Bevacizumab

Start the discussion